This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
← catalyst calendarSponsored by Beam Therapeutics Inc. (industry) · BEAM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Basic science
Enrollment
30estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-27 | actual | When the study began enrolling |
| Primary completion | 2026-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Subjects
- Healthy Participant Study
Interventions
- Drug: BEAM-103
- Drug: Placebo Comparator
Primary outcome
what the primary-completion date above is the date OFTo determine the safety and tolerability of single ascending doses of BEAM-103
measured from enrollment to the end of study at 5 months
Permalink · BEAM's whole pipeline · Catalyst calendar · Every registered study · What changed